Cancer
Regeneron shares data for multiple myeloma treatment
December 8, 2023Medical Communications Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …
First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment
November 9, 2023Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer
AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
October 30, 2023Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …
Nuvectis Pharma initiates phase 1a NXP900 clinical trial
September 13, 2023Research and Development Cancer, Nuvectis Pharma, Oncology, clinical trial
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, …
Zumutor’s cancer drug trial cleared by FDA
August 14, 2023Research and Development Cancer, Oncology, clinical trial, pharmaceutical
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its ZM008 drug for cancer had …
Targeted chemotherapy to kill all solid tumours developed in preclinical research
August 3, 2023Research and Development Cancer, Oncology, chemotherapy, pharmaceutical, tumour
Researchers from the City of Hope organisation in the US have released a study confirming the development of AOH1996, a …
EMA accepts Astellas’ MAA for Zolbetuximab
July 14, 2023Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …
CellCentric announces $25m investment from Pfizer
July 12, 2023Business Services Cancer, CellCentric, Oncology, Pfizer, collaboration, investment
UK-based biotechnology company CellCentric has announced a strategic investment from Pfizer including $25m to finance further development of inobrodib, its …
Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment
July 10, 2023Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix
Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …
UK nonprofit National Cancer Research Institute to close
June 27, 2023Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology
The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years of advancing cancer research. Established …
XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets
June 23, 2023Sales and Marketing Cancer, Oncology, Xoma, acquisition, oncology
US-based biotechnology royalty aggregator XOMA has announced that it has gained the royalty and milestone rights for two assets from …
GSK settles first Zantac lawsuit due for trial in US
June 23, 2023Medical Communications Cancer, GSK, Pharmacy, Zantac, lawsuit
UK-based pharmaceutical and biotechnology company GSK has reached a settlement with a US man who claims the drugmaker’s heartburn medicine …
Kymera Therapeutics reports positive data in cancer drug trials
June 14, 2023Research and Development Cancer, Kymera Therapeutics, Oncology, autoimmune diseases, clinical trials, inflammatory diseases
US clinical-stage biopharmaceutical company Kymera Therapeutics has shared new data regarding its oncology programmes KT-333 and KT-413, highlighting their robust dose-dependent …
AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment
June 9, 2023Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma
UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …
Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation
June 8, 2023Research and Development Cancer, FDA, Haematology, Innate Pharma, Sanofi, haematology
Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US Food and Drug Administration (FDA) …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
